|
||
|
Pharmexa
Download PDF Members: Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epitope-based vaccines for cancer and infectious diseases.Pharmexa's lead programs include a proprietary peptide vaccine targeting telomerase in phase III, a recombinant protein vaccine targeting HER-2 currently in phase II and several vaccine candidates for HIV therapy and prophylaxis currently in phase I. Earlier programs target RANKL, TNF-alpha, malaria, influenza and other promising targets
This page has been viewed 173 times since April 2007, the link to the organisation's website has been followed 23 times Recent Search Terms used to find this page: Pharmexa | pharmexa | pharmexa | Pharmexa | Pharmexa | f | . Search for more companies in Hørsholm This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Pharmexa | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|